3D image-guided robot-assisted surgery for complex kidney tumors
Official title: A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)
Run by University Hospital, Grenoble · NCT05572216 · Data updated 2026-11-12
This study is testing a new robot-assisted surgery technique for complex kidney tumors to see if it leads to fewer complications and better long-term kidney function compared to the standard method.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 694 (estimated) |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 2 sites (Grenoble and 1 other locations) |
| Status | Recruiting |
| Started | January 24, 2023 |
| Main results expected | January 24, 2023 |
| Study ends | November 2027 |
| Registry record updated | November 18, 2024 |
| Trial ID | NCT05572216 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 with moderate or high complexity renal tumors who are eligible for robot-assisted surgery.
✕Probably not a fit
Patients with medical contraindications to robot-assisted surgery or those with renal insufficiency that prevents iodine injection may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the outcomes of a new surgical technique called 3D Image-Guided Robot-Assisted Partial Nephrectomy (3D IG-RAPN) compared to the conventional Robot-Assisted Partial Nephrectomy (RAPN) for patients with moderate to highly complex renal tumors. The study aims to assess peri-operative complications, oncological safety, and long-term renal function preservation. Participants will undergo the experimental procedure, and researchers will analyze the results to determine if the new approach offers better outcomes. The trial will be conducted across 12 high-volume urological centers within the UroCCR Network.
Why it matters
Potential benefit: If successful, this approach could lead to improved surgical outcomes and long-term health for patients with complex renal tumors.
How similar studies have gone: While the use of augmented reality in surgery is an emerging field, this specific approach has not been widely tested, making it a novel investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years * Indication of RAPN for suspicious renal tumor * Moderate or high complexity renal tumor (RENAL Nephrometry Score (NS) \>7) * Da Vinci® surgical system available for the surgery * Patient affiliated to the French social security system or an equivalent system * Signed informed consent form UroCCR and ACCURATE Exclusion Criteria: * Medical contraindication to RAPN * Renal insufficiency forbidding iodine injection * Patient with allergy to iodinated contrast products * Patient concerned by articles L1121-5 to 8 of the French public health code (protected persons)
Where it's running
-
University Hospital Grenoble
Grenoble, France Recruiting -
university HospitalGrenoble
Grenoble, France Recruiting
Study contacts
- Principal investigator: Jean-Luc DESCOTES, Pr — University Hospital, Grenoble
- Study coordinator: Jean-Luc DESCOTES, Pr
- Email: jldescotes@chu-grenoble.fr
- Phone: 0476767642
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
-
MRI-based AI to classify and grade renal tumors
This study tests AI methods on MRI data from adults with kidney tumors to see if they can identify tumor type and grade before surgery.
-
Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance
This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.
-
Hospital admissions for blood in the urine
This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
-
Spectral CT during embolization and ablation for liver and kidney tumors
This pilot tries a new spectral CT technique during image-guided embolization and ablation for adults with liver or kidney tumors to see if it improves image quality and helps guide treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.